Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05341557 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Primary completion date: Jun 1, 2024 to Dec 2026 · Completion date: Jun 1, 2025 to Apr 2027 · Start date changed from estimate of Jun 2022 to Aug 29, 2022 · 1 morev3 Show 4 more changesShow less
    • Primary completion date: Jun 1, 2024 to Dec 2026
    • Completion date: Jun 1, 2025 to Apr 2027
    • Start date changed from estimate of Jun 2022 to Aug 29, 2022
    • Site details revised at 4 of 4 sites
  2. Start date: Jun 1, 2022 to Jun 2022v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A first-in-human study to evaluate the safety, tolerability and maximum tolerated dose (MTD) and establish the recommended phase 2 dose (RP2D) of BPI-371153, a PD-L1 Inhibitor, in patients with advanced solid tumors or relapsed/refractory lymphoma.
Trial Details
NCT Number NCT05341557
Lead Sponsor Betta Pharmaceuticals Co., Ltd.
Conditions Advanced Solid Tumor, Lymphoma, NSCLC, HCC
Enrollment 110 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov